Innovent Biologics, Inc. (OTCMKTS:IVBXF) Sees Significant Increase in Short Interest

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 1,029,572 shares, a growth of 4,520.0% from the June 30th total of 22,285 shares. Based on an average daily volume of 2,991 shares, the short-interest ratio is currently 344.2 days.

Innovent Biologics Trading Down 15.4%

IVBXF traded down $1.97 during trading on Friday, hitting $10.83. 539 shares of the stock traded hands, compared to its average volume of 4,384. Innovent Biologics has a 12-month low of $9.10 and a 12-month high of $15.12. The firm has a 50-day moving average of $10.57 and a 200 day moving average of $10.72.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).